The objective of the present study was to assess the effect of combining CBT-I with wearing blue-light blocking glasses 90 min prior to bedtime on subjective and objective sleep parameters and daily symptoms (anxiety, depression, hyperarousal). Thirty patients (mean age 48.1 ± 16.13 years, range 21-71, 15 men/15 women) completed a CBT-I group therapy program, with groups randomly assigned to either "active" (blue-light filtering glasses) condition or "placebo" (glasses without filtering properties) condition. Patients were continually monitored by wristwatch actigraphy, kept their sleep diaries and completed a standard questionnaire battery at admission and after the end of the program. Statistical analyses showed a greater reduction of BAI score in "active" (4.33 ± 4.58) versus "placebo" (-0.92 ± 3.68) groups of patients [F = 6.389, p = .019, Cohen's d = 1.26] and significant prolongation of subjective total sleep time in "active" (-36.88 ± 48.68 min.) versus "placebo" (7.04 ± 47.50 min.) [F = 8.56, p < .01, d = 0.91] group. When pre- and post-treatment results were compared in both groups separately, using paired-samples t-tests, significant differences were observed also in the active group for BDI-II score (t = 3.66, p = .003, Cohen's d = 0.95) and HAS score (t = 2.90, p = .012, Cohen's d = 0.75). No significant differences were found in the placebo group. In active group, there was also a significant reduction of subjective sleep latency (t = 2.65, p = .021, d = 0.73) and an increase of subjective total sleep time (t = -2.73, p = .018, d = -0.76) without change in objective sleep duration which was significantly shortened in the placebo group. We provide further evidence that blocking short-wavelength light in the evening hours may be beneficial for patients suffering from insomnia.

中文翻译：

---

阻挡光线并睡个好觉：夜间蓝光过滤作为失眠认知行为疗法的一部分。

本研究的目的是评估在睡前 90 分钟将 CBT-I 与戴蓝光阻挡眼镜相结合对主观和客观睡眠参数和日常症状（焦虑、抑郁、过度觉醒）的影响。30 名患者（平均年龄 48.1 ± 16.13 岁，范围 21-71，15 名男性/15 名女性）完成了 CBT-I 团体治疗计划，各组随机分配到“主动”（滤蓝光眼镜）状态或“安慰剂”组"（没有过滤特性的眼镜）条件。患者在入院时和项目结束后通过手表活动记录仪持续监测，记录他们的睡眠日记并完成标准问卷调查。统计分析显示，“积极”（4.33 ± 4.58）与“安慰剂”（-0.92 ± 3）相比，BAI 评分降低幅度更大。68) 组患者 [F = 6.389, p = .019, Cohen's d = 1.26] 和“积极”（-36.88 ± 48.68 分钟）与“安慰剂”（7.04 ± 47.50 分钟）的主观总睡眠时间显着延长。 ) [F = 8.56, p < .01, d = 0.91] 组。当使用配对样本 t 检验分别比较两组治疗前和治疗后的结果时，在 BDI-II 评分的活动组中也观察到显着差异（t = 3.66，p = .003，Cohen's d = 0.95) 和 HAS 评分 (t = 2.90, p = .012, Cohen's d = 0.75)。在安慰剂组中没有发现显着差异。在活动组中，主观睡眠潜伏期也显着减少（t = 2.65，p = .021，d = 0.73），主观总睡眠时间增加（t = -2.73，p = .018，d = - 0。76）客观睡眠时间没有变化，安慰剂组显着缩短。我们提供了进一步的证据，表明在晚上阻挡短波光可能对失眠患者有益。